blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4039260

EP4039260 - CD62LLOW CD4+ T-CELLS FOR TREATING OR PREVENTING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.02.2025
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  15.03.2024
FormerGrant of patent is intended
Status updated on  08.11.2023
FormerExamination is in progress
Status updated on  14.10.2023
FormerGrant of patent is intended
Status updated on  15.06.2023
FormerExamination is in progress
Status updated on  21.04.2023
FormerRequest for examination was made
Status updated on  10.02.2023
FormerThe application has been published
Status updated on  08.07.2022
Most recent event   Tooltip19.09.2025Lapse of the patent in a contracting state
New state(s): MC		published on 22.10.2025  [2025/43]
Applicant(s)For all designated states
Saitama Medical University
38, Morohongo Moroyama-machi
Iruma-gun, Saitama 350-0495 / JP
[2022/32]
Inventor(s)01 / KAGAMU, Hiroshi
Iruma-gun Saitama 350-0495 / JP
 [2022/32]
Representative(s)Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
[2022/32]
Application number, filing date22153621.206.02.2018
[2022/32]
Priority number, dateJP2017002068507.02.2017         Original published format: JP 2017020685
JP2017011006902.06.2017         Original published format: JP 2017110069
[2022/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4039260
Date:10.08.2022
Language:EN
[2022/32]
Type: B1 Patent specification 
No.:EP4039260
Date:17.04.2024
Language:EN
[2024/16]
Search report(s)(Supplementary) European search report - dispatched on:EP30.06.2022
ClassificationIPC:A61K35/17, G01N33/574
[2022/32]
CPC:
G01N33/5759 (EP,KR,US); A61K40/11 (EP,KR,US); A61K40/42 (EP,US);
A61K45/06 (KR); A61P35/00 (EP,KR); C07K16/18 (US);
C07K16/2812 (US); C07K16/2818 (EP); G01N33/5011 (EP,KR);
A61K2039/505 (EP,KR); A61K2039/545 (EP,KR); A61K2239/31 (EP,US);
A61K2239/38 (EP,US); A61K2239/57 (EP,US); A61K2300/00 (KR);
G01N2333/70514 (US); G01N2333/70564 (US); G01N2333/7155 (US);
G01N2800/52 (EP,KR); G01N33/505 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/11]
Former [2022/32]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:CD62LLOW CD4+ T-ZELLEN ZUR BEHANDLUNG ODER VORBEUGUNG VON KREBS[2022/32]
English:CD62LLOW CD4+ T-CELLS FOR TREATING OR PREVENTING CANCER[2022/32]
French:CELLULES T CD62LLOW CD4+ POUR TRAITER OU PRÉVENIR LE CANCER[2022/32]
Examination procedure08.02.2023Amendment by applicant (claims and/or description)
08.02.2023Examination requested  [2023/11]
08.02.2023Date on which the examining division has become responsible
21.04.2023Despatch of a communication from the examining division (Time limit: M04)
28.04.2023Reply to a communication from the examining division
16.06.2023Communication of intention to grant the patent
13.10.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.10.2023Fee for grant paid
13.10.2023Fee for publishing/printing paid
16.11.2023Communication of intention to grant the patent
06.03.2024Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP18708226.8  / EP3580569
Opposition(s)20.01.2025No opposition filed within time limit [2025/13]
Fees paidRenewal fee
27.01.2022Renewal fee patent year 03
27.01.2022Renewal fee patent year 04
27.01.2022Renewal fee patent year 05
30.01.2023Renewal fee patent year 06
23.02.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.04.2024
BG17.04.2024
CZ17.04.2024
DK17.04.2024
EE17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
IT17.04.2024
LV17.04.2024
MC17.04.2024
NL17.04.2024
PL17.04.2024
RO17.04.2024
SE17.04.2024
SI17.04.2024
SK17.04.2024
SM17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
[2025/43]
Former [2025/42]AT17.04.2024
BG17.04.2024
CZ17.04.2024
DK17.04.2024
EE17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
IT17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
RO17.04.2024
SE17.04.2024
SI17.04.2024
SK17.04.2024
SM17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2025/23]AT17.04.2024
BG17.04.2024
CZ17.04.2024
DK17.04.2024
EE17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
IT17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
RO17.04.2024
SI17.04.2024
SK17.04.2024
SM17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2025/11]AT17.04.2024
BG17.04.2024
CZ17.04.2024
DK17.04.2024
EE17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
IT17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
RO17.04.2024
SK17.04.2024
SM17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2025/09]AT17.04.2024
BG17.04.2024
DK17.04.2024
EE17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2025/08]AT17.04.2024
BG17.04.2024
DK17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2024/50]AT17.04.2024
BG17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
LV17.04.2024
NL17.04.2024
PL17.04.2024
NO17.07.2024
RS17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2024/48]AT17.04.2024
BG17.04.2024
ES17.04.2024
FI17.04.2024
HR17.04.2024
NL17.04.2024
NO17.07.2024
GR18.07.2024
IS17.08.2024
PT19.08.2024
Former [2024/44]NL17.04.2024
Documents cited:Search[XA] EP1870452  (UNIV KYOTO et al.)
 [XA]   WANG LI-XIN ET AL: "Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 2, no. 1, 26 November 2004 (2004-11-26), pages 41, XP021009844, ISSN: 1479-5876, DOI: 10.1186/1479-5876-2-41

DOI:   http://dx.doi.org/10.1186/1479-5876-2-41
 [XA]   H KAGAMU ET AL: "Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950), 1 April 1998 (1998-04-01), UNITED STATES, pages 3444, XP055464785, Retrieved from the Internet
 [XA]   K. KOYAMA ET AL: "Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage", CLINICAL CANCER RESEARCH, vol. 14, no. 21, 1 November 2008 (2008-11-01), US, pages 6770 - 6779, XP055464766, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1156

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-08-1156
by applicantUS6040177
   BRAHMER J ET AL., N ENGL J MED, vol. 373, 2015, pages 123 - 135
   OKAZAKI, T.CHIKUMA, S.IWAI, Y. ET AL.: "A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application", NAT. IMMUNOL., vol. 14, 2013, pages 1212 - 1218
   SNINSKY, J. J. ET AL.: "Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", 1999, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE
   AUSUBEL, F. M.: "Current Protocols in Molecular Biology", 1987, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE
   INNIS, M. A.: "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS
   INNIS, M. A. ET AL.: "A Compendium of Methods from Current Protocols in Molecular Biology", 1995, GREENE PUB. ASSOCIATES
   YODOSHA: "Idenshi Donyu Oyobi Hatsugen Kaiseki Jikken Ho", BESSATSU JIKKEN IGAKU, 1997
   HUI, E. ET AL.: "T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition", SCIENCE, vol. 355, 2017, pages 1428 - 1433
   BAIXERAS, E. ET AL.: "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens", J EXP MED, vol. 176, 1992, pages 327 - 337, XP000672285, DOI: 10.1084/jem.176.2.327

DOI:   http://dx.doi.org/10.1084/jem.176.2.327
   WORKMAN, C.J. ET AL.: "Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo", J IMMUNOL, vol. 172, 2004, pages 5450 - 5455
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.